What is Zhengye Biotechnology's operating income?

Zhengye Biotechnology's total operating income in 2025 was -$10.08 million, based on the following breakdown: Total Gross Profit: $3.41 million Total Operating Expenses: $13.29 million

Trading of Zhengye Biotechnology was halted at 10:29 AM EST due to "LULD Pause".

Zhengye Biotechnology (ZYBT) Financials

$2.43 -5.58 (-69.68%)

As of 01:41 PM Eastern

Compare

Annual Income Statements for Zhengye Biotechnology

This table shows Zhengye Biotechnology's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2022	2023	2024	2025
Period end date	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Net Income / (Loss) Attributable to Common Shareholders	6.78	4.43	1.55	-9.98
Consolidated Net Income / (Loss)	8.08	5.28	1.85	-12
Net Income / (Loss) Continuing Operations	8.08	5.28	1.82	-12
Total Pre-Tax Income	9.27	6.16	1.97	-10
Total Operating Income	9.55	6.34	2.25	-10
Total Gross Profit	21	17	13	3.41
Total Revenue	38	30	26	17
Operating Revenue	38	30	26	17
Total Cost of Revenue	18	13	13	13
Operating Cost of Revenue	16	13	13	13
Other Cost of Revenue	1.41	-0.52	-0.24	0.21
Total Operating Expenses	10	11	10	13
Selling, General & Admin Expense	3.53	3.32	3.09	4.43
Marketing Expense	5.01	5.74	5.65	6.28
Research & Development Expense	1.95	1.68	1.75	2.58
Total Other Income / (Expense), net	-0.28	-0.17	-0.31	-0.21
Interest Expense	0.41	0.62	0.55	0.49
Interest & Investment Income	0.02	0.04	0.03	0.01
Other Income / (Expense), net	0.12	0.41	0.21	0.26
Income Tax Expense	1.18	0.88	0.13	1.59
Net Income / (Loss) Attributable to Noncontrolling Interest	1.31	0.85	0.30	-1.89
Basic Earnings per Share	$0.15	$0.19	$0.07	($0.06)
Weighted Average Basic Shares Outstanding	45.67M	45.67M	45.67M	47.35M
Diluted Earnings per Share	$0.15	$0.19	$0.07	($0.06)
Weighted Average Diluted Shares Outstanding	45.67M	45.67M	45.67M	47.35M
Weighted Average Basic & Diluted Shares Outstanding	-	-	45.67M	47.39M

No quarterly income statements for Zhengye Biotechnology are available.

This table details how cash moves in and out of Zhengye Biotechnology's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2022	2023	2024	2025
Period end date	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Net Change in Cash & Equivalents	0.50	2.46	-1.18	4.72
Net Cash From Operating Activities	2.51	6.79	5.62	1.91
Net Cash From Continuing Operating Activities	2.51	6.79	6.14	1.91
Net Income / (Loss) Continuing Operations	8.08	5.28	1.85	-12
Consolidated Net Income / (Loss)	8.08	5.28	1.85	-12
Depreciation Expense	2.73	3.37	3.31	3.70
Amortization Expense	-	0.00	0.00	0.01
Non-Cash Adjustments To Reconcile Net Income	-1.84	1.89	0.60	5.45
Changes in Operating Assets and Liabilities, net	-6.46	-3.76	0.38	4.61
Net Cash From Investing Activities	-3.96	-1.66	-3.79	-1.81
Net Cash From Continuing Investing Activities	-3.96	-1.66	-4.30	-1.81
Purchase of Property, Plant & Equipment	-3.96	-1.04	-1.86	-0.14
Acquisitions	0.00	-0.59	-1.94	-1.66
Purchase of Investments	0.00	-0.17	0.00	-1.00
Sale of Property, Plant & Equipment	0.00	0.15	0.01	0.00
Sale and/or Maturity of Investments	-	0.00	0.00	1.00
Net Cash From Financing Activities	1.95	-2.67	-3.03	4.62
Net Cash From Continuing Financing Activities	1.95	-2.67	-3.03	4.62
Repayment of Debt	-9.42	-7.73	-13	-12
Repurchase of Common Equity	0.00	-0.63	-0.48	0.00
Payment of Dividends	-3.11	-5.56	-2.20	0.00
Issuance of Debt	14	11	12	10
Issuance of Common Equity	-	0.00	0.00	6.16
Other Financing Activities, net	-	0.00	-	0.21
Cash Interest Paid	0.41	0.62	0.55	0.48
Cash Income Taxes Paid	1.23	1.48	0.02	0.00

No quarterly cash flow statements for Zhengye Biotechnology are available.

This table presents Zhengye Biotechnology's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2023	2024	2025
Period end date	12/31/2023	12/31/2024	12/31/2025
Total Assets	70	68	62
Total Current Assets	27	24	20
Cash & Equivalents	2.12	2.55	7.20
Restricted Cash	1.71	0.00	0.00
Short-Term Investments	0.17	0.20	0.22
Note & Lease Receivable	3.27	3.51	0.00
Accounts Receivable	11	8.16	2.64
Inventories, net	8.65	9.45	5.92
Prepaid Expenses	-	0.36	3.67
Plant, Property, & Equipment, net	37	35	34
Total Noncurrent Assets	6.78	8.39	8.90
Intangible Assets	2.30	2.03	6.73
Noncurrent Deferred & Refundable Income Taxes	1.68	1.51	0.00
Other Noncurrent Operating Assets	2.81	4.85	2.17
Total Liabilities & Shareholders' Equity	70	68	62
Total Liabilities	23	19	19
Total Current Liabilities	21	19	17
Short-Term Debt	11	11	9.41
Accounts Payable	6.84	6.66	6.79
Current Deferred & Payable Income Tax Liabilities	0.32	0.28	0.34
Other Current Liabilities	0.55	0.50	0.69
Total Noncurrent Liabilities	1.46	0.66	1.33
Long-Term Debt	1.46	0.66	1.27
Noncurrent Deferred & Payable Income Tax Liabilities	-	0.00	0.01
Other Noncurrent Operating Liabilities	-	0.00	0.05
Commitments & Contingencies	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	48	48	44
Total Preferred & Common Equity	38	39	36
Total Common Equity	38	39	36
Common Stock	29	28	34
Retained Earnings	5.41	6.60	-3.09
Accumulated Other Comprehensive Income / (Loss)	0.00	0.00	-0.28
Other Equity Adjustments	4.41	4.47	4.67
Noncontrolling Interest	9.36	9.40	8.13

No quarterly balance sheets for Zhengye Biotechnology are available.

This table displays calculated financial ratios and metrics derived from Zhengye Biotechnology's official financial filings.

Metric	2022	2023	2024	2025
Period end date	12/31/2022	12/31/2023	12/31/2024	12/31/2025
DEI Shares Outstanding	0.00	0.00	0.00	0.00
DEI Adjusted Shares Outstanding	0.00	0.00	0.00	0.00
DEI Earnings Per Adjusted Shares Outstanding	0.00	0.00	0.00	0.00
Growth Metrics	-	-	-	-
Revenue Growth	0.00%	-21.00%	-14.36%	-34.83%
EBITDA Growth	0.00%	-18.38%	-42.87%	-205.82%
EBIT Growth	0.00%	-30.21%	-63.43%	-498.42%
NOPAT Growth	0.00%	-34.76%	-61.19%	-434.87%
Net Income Growth	0.00%	-34.63%	-65.07%	-742.92%
EPS Growth	0.00%	31.44%	-64.81%	-187.72%
Operating Cash Flow Growth	0.00%	170.02%	-17.14%	-66.09%
Free Cash Flow Firm Growth	0.00%	0.00%	106.41%	-5.58%
Invested Capital Growth	0.00%	0.00%	-2.22%	-17.91%
Revenue Q/Q Growth	0.00%	0.00%	0.00%	0.00%
EBITDA Q/Q Growth	0.00%	0.00%	0.00%	0.00%
EBIT Q/Q Growth	0.00%	0.00%	0.00%	0.00%
NOPAT Q/Q Growth	0.00%	0.00%	0.00%	0.00%
Net Income Q/Q Growth	0.00%	0.00%	0.00%	0.00%
EPS Q/Q Growth	0.00%	0.00%	0.00%	0.00%
Operating Cash Flow Q/Q Growth	0.00%	0.00%	0.00%	0.00%
Free Cash Flow Firm Q/Q Growth	0.00%	0.00%	0.00%	0.00%
Invested Capital Q/Q Growth	0.00%	0.00%	0.00%	0.00%
Profitability Metrics	-	-	-	-
Gross Margin	56.82%	55.52%	48.99%	20.51%
EBITDA Margin	32.83%	33.92%	22.62%	-36.73%
Operating Margin	25.29%	21.25%	8.82%	-60.59%
EBIT Margin	25.60%	22.62%	9.66%	-59.04%
Profit (Net Income) Margin	21.42%	17.72%	7.23%	-71.30%
Tax Burden Percent	87.21%	85.71%	93.58%	115.44%
Interest Burden Percent	95.91%	91.41%	79.98%	104.62%
Effective Tax Rate	12.79%	14.29%	6.42%	0.00%
Return on Invested Capital (ROIC)	0.00%	18.50%	3.63%	-13.51%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	15.80%	1.01%	-91.35%
Return on Net Nonoperating Assets (RNNOA)	0.00%	3.61%	0.21%	-12.24%
Return on Equity (ROE)	0.00%	22.11%	3.84%	-25.75%
Cash Return on Invested Capital (CROIC)	0.00%	-181.50%	5.88%	6.17%
Operating Return on Assets (OROA)	0.00%	9.58%	3.57%	-15.11%
Return on Assets (ROA)	0.00%	7.50%	2.67%	-18.25%
Return on Common Equity (ROCE)	0.00%	17.78%	3.09%	-20.85%
Return on Equity Simple (ROE_SIMPLE)	0.00%	0.00%	0.00%	0.00%
Net Operating Profit after Tax (NOPAT)	8.32	5.43	2.11	-7.06
NOPAT Margin	22.06%	18.22%	8.26%	-42.41%
Net Nonoperating Expense Percent (NNEP)	0.00%	2.71%	2.62%	77.84%
Return On Investment Capital (ROIC_SIMPLE)	-	8.98%	3.50%	-12.94%
Cost of Revenue to Revenue	46.92%	42.73%	50.05%	80.72%
SG&A Expenses to Revenue	9.34%	11.15%	12.11%	26.65%
R&D to Revenue	5.16%	5.62%	6.87%	15.48%
Operating Expenses to Revenue	27.78%	36.02%	41.12%	79.87%
Earnings before Interest and Taxes (EBIT)	9.66	6.74	2.47	-9.82
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	12	10	5.78	-6.11
Valuation Ratios	-	-	-	-
Price to Book Value (P/BV)	0.00	0.16	0.15	1.52
Price to Tangible Book Value (P/TBV)	0.00	0.17	0.16	1.88
Price to Revenue (P/Rev)	0.16	0.20	0.24	3.27
Price to Earnings (P/E)	0.89	1.35	3.87	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%
Earnings Yield	112.93%	73.84%	25.83%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	0.41	0.43	1.40
Enterprise Value to Revenue (EV/Rev)	0.00	0.81	0.96	3.96
Enterprise Value to EBITDA (EV/EBITDA)	0.00	2.38	4.24	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	3.57	9.93	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	4.43	11.62	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	3.55	4.36	34.53
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	7.18	20.43
Leverage & Solvency	-	-	-	-
Debt to Equity	0.00	0.27	0.25	0.24
Long-Term Debt to Equity	0.00	0.03	0.01	0.03
Financial Leverage	0.00	0.23	0.21	0.13
Leverage Ratio	0.00	1.47	1.44	1.41
Compound Leverage Factor	0.00	1.35	1.15	1.48
Debt to Total Capital	0.00%	21.01%	19.69%	19.57%
Short-Term Debt to Total Capital	0.00%	18.59%	18.60%	17.25%
Long-Term Debt to Total Capital	0.00%	2.42%	1.09%	2.32%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	15.46%	15.62%	14.91%
Common Equity to Total Capital	0.00%	63.53%	64.69%	65.51%
Debt to EBITDA	0.00	1.26	2.05	-1.75
Net Debt to EBITDA	0.00	0.86	1.57	-0.53
Long-Term Debt to EBITDA	0.00	0.14	0.11	-0.21
Debt to NOPAT	0.00	2.34	5.62	-1.51
Net Debt to NOPAT	0.00	1.60	4.32	-0.46
Long-Term Debt to NOPAT	0.00	0.27	0.31	-0.18
Altman Z-Score	0.00	1.10	0.92	1.49
Noncontrolling Interest Sharing Ratio	0.00%	19.58%	19.52%	19.02%
Liquidity Ratios	-	-	-	-
Current Ratio	0.00	1.26	1.31	1.14
Quick Ratio	0.00	0.77	0.77	0.58
Cash Flow Metrics	-	-	-	-
Free Cash Flow to Firm (FCFF)	0.00	-53	3.41	3.22
Operating Cash Flow to CapEx	63.43%	760.36%	304.52%	1,322.72%
Free Cash Flow to Firm to Interest Expense	0.00	-85.51	6.16	6.63
Operating Cash Flow to Interest Expense	6.11	10.89	10.15	3.92
Operating Cash Flow Less CapEx to Interest Expense	-3.52	9.46	6.82	3.63
Efficiency Ratios	-	-	-	-
Asset Turnover	0.00	0.42	0.37	0.26
Accounts Receivable Turnover	0.00	2.80	2.72	3.08
Inventory Turnover	0.00	1.47	1.41	1.75
Fixed Asset Turnover	0.00	0.80	0.71	0.48
Accounts Payable Turnover	0.00	1.86	1.89	2.00
Days Sales Outstanding (DSO)	0.00	130.15	134.31	118.49
Days Inventory Outstanding (DIO)	0.00	247.87	258.54	208.84
Days Payable Outstanding (DPO)	0.00	195.93	192.68	182.66
Cash Conversion Cycle (CCC)	0.00	182.09	200.17	144.67
Capital & Investment Metrics	-	-	-	-
Invested Capital	0.00	59	57	47
Invested Capital Turnover	0.00	1.02	0.44	0.32
Increase / (Decrease) in Invested Capital	0.00	59	-1.31	-10
Enterprise Value (EV)	0.00	24	24	66
Market Capitalization	6.00	6.00	6.00	54
Book Value per Share	$0.00	$0.84	$0.85	$0.75
Tangible Book Value per Share	$0.00	$0.79	$0.81	$0.61
Total Capital	0.00	60	60	55
Total Debt	0.00	13	12	11
Total Long-Term Debt	0.00	1.46	0.66	1.27
Net Debt	0.00	8.71	9.10	3.25
Capital Expenditures (CapEx)	3.96	0.89	1.85	0.14
Debt-free, Cash-free Net Working Capital (DFCFNWC)	0.00	13	14	4.41
Debt-free Net Working Capital (DFNWC)	0.00	17	17	12
Net Working Capital (NWC)	0.00	5.49	5.71	2.42
Net Nonoperating Expense (NNE)	0.24	0.15	0.26	4.81
Net Nonoperating Obligations (NNO)	0.00	11	9.10	3.25
Total Depreciation and Amortization (D&A)	2.73	3.37	3.31	3.71
Debt-free, Cash-free Net Working Capital to Revenue	0.00%	42.74%	55.41%	26.51%
Debt-free Net Working Capital to Revenue	0.00%	56.16%	66.16%	71.11%
Net Working Capital to Revenue	0.00%	18.43%	22.35%	14.56%
Earnings Adjustments	-	-	-	-
Adjusted Basic Earnings per Share	$0.00	$0.00	$0.00	($0.06)
Adjusted Weighted Average Basic Shares Outstanding	0.00	0.00	45.67M	47.35M
Adjusted Diluted Earnings per Share	$0.00	$0.00	$0.00	($0.06)
Adjusted Weighted Average Diluted Shares Outstanding	0.00	0.00	45.67M	47.35M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	0.00	0.00	45.67M	47.39M
Normalized Net Operating Profit after Tax (NOPAT)	8.32	5.43	2.11	-7.06
Normalized NOPAT Margin	22.06%	18.22%	8.26%	-42.41%
Pre Tax Income Margin	24.56%	20.68%	7.72%	-61.77%
Debt Service Ratios	-	-	-	-
EBIT to Interest Expense	23.47	10.82	4.45	-20.20
NOPAT to Interest Expense	20.22	8.72	3.81	-14.52
EBIT Less CapEx to Interest Expense	13.85	9.39	1.12	-20.50
NOPAT Less CapEx to Interest Expense	10.60	7.28	0.47	-14.81
Payout Ratios	-	-	-	-
Dividend Payout Ratio	38.44%	105.18%	118.95%	0.00%
Augmented Payout Ratio	38.44%	117.17%	145.04%	0.00%

No quarterly metrics and ratios for Zhengye Biotechnology are available.

Financials Breakdown Chart

Zhengye Biotechnology Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Zhengye Biotechnology's fiscal year ends in December. Their fiscal year 2025 ended on December 31, 2025.

Zhengye Biotechnology's net income appears to be on a downward trend, with a most recent value of -$11.86 million in 2025, falling from $8.08 million in 2022. The previous period was $1.85 million in 2024. Find out what analysts predict for Zhengye Biotechnology in the coming months.

Zhengye Biotechnology's total operating income in 2025 was -$10.08 million, based on the following breakdown:

Total Gross Profit: $3.41 million
Total Operating Expenses: $13.29 million

Over the last 3 years, Zhengye Biotechnology's total revenue changed from $37.74 million in 2022 to $16.64 million in 2025, a change of -55.9%.

Zhengye Biotechnology's total liabilities were at $18.56 million at the end of 2025, a 3.7% decrease from 2024, and a 18.0% decrease since 2023.

In the past 2 years, Zhengye Biotechnology's cash and equivalents has ranged from $2.12 million in 2023 to $7.20 million in 2025, and is currently $7.20 million as of their latest financial filing in 2025.

Over the last 3 years, Zhengye Biotechnology's book value per share changed from 0.00 in 2022 to 0.75 in 2025, a change of 75.5%.

Related Companies

Financial statements for NASDAQ:ZYBT last updated on 7/16/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Zhengye Biotechnology (ZYBT) Financials

Financials Breakdown Chart

Zhengye Biotechnology Financials - Frequently Asked Questions

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Zhengye Biotechnology (ZYBT) Financials

Annual Income Statements for Zhengye Biotechnology

Quarterly Income Statements for Zhengye Biotechnology

Annual Cash Flow Statements for Zhengye Biotechnology

Quarterly Cash Flow Statements for Zhengye Biotechnology

Annual Balance Sheets for Zhengye Biotechnology

Quarterly Balance Sheets for Zhengye Biotechnology

Annual Metrics And Ratios for Zhengye Biotechnology

Quarterly Metrics And Ratios for Zhengye Biotechnology

Financials Breakdown Chart

Zhengye Biotechnology Financials - Frequently Asked Questions

When does Zhengye Biotechnology's financial year end?

How has Zhengye Biotechnology's net income changed over the last 3 years?

What is Zhengye Biotechnology's operating income?

How has Zhengye Biotechnology's revenue changed over the last 3 years?

How much debt does Zhengye Biotechnology have?

How much cash does Zhengye Biotechnology have?

How has Zhengye Biotechnology's book value per share changed over the last 3 years?

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools